| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 874.5 | 804.6 |
| Gross profit | 347.4 | 294.3 |
| Profit before tax | 267.7 | 171.9 |
| Net income | 214.0 | 140.0 |
| EPS (diluted, $ a share) | $3.02 | $1.92 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +52.9% |
|---|---|
| Revenue, year on year | +8.7% |
| Gross margin | 39.7% |
| Operating margin | 30.6% |
10-Q filed with the SEC, NYSE: WST. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
West Pharmaceutical Services Inc: key numbers
- Share price
- $417.80Close, Nov 16
- Market cap
- $29.1B
- Shares outstanding
- 69.66MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from West Pharmaceutical Services Inc
All →West Pharmaceutical Services Financial Results
West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million, an 8.7% increase driven by strong organic growth in its High-Value Product (HVP) Components business. Due to the strong performance, the company raised its full-year 2026 net sales guidance to a range of $3.41 billion to $3.42 billion and its adjusted-diluted EPS guidance to $9.38 to $9.48.
- Term
- Q3 2026
“I am pleased to report strong third-quarter 2026 results, with net sales and adjusted EPS exceeding our expectations. Our results were again led by our High-Value Product (HVP) Components business. The robust sales performance drove strong operating income margin expansion and EPS growth. As a result of our team's strong execution in the third quarter, we are increasing our full-year 2026 guidance.”
Michel Lagarde, President and Chief Executive Officer
“I want to thank our global teams for their relentless focus on execution to deliver products and services for our customers and the patients they serve. West is a critical primary containment and drug delivery partner for pharmaceutical companies, biotechs and CDMOs around the world. We are grateful for the trust our customers put in us, and we remain committed to driving continuous improvement to even better serve their current and future needs.”
Michel Lagarde, President and Chief Executive Officer
West Pharmaceutical Services $200M Debt Financing with Bank of America, N.A.
West Pharmaceutical Services entered into a new $950 million credit facility consisting of a $750 million revolving credit facility and a $200 million term loan. The proceeds were used to repay $130 million outstanding under its previous 2019 credit agreement, which was subsequently terminated. The new facility has a five-year term and will be used for working capital, capital expenditures, and general corporate purposes.
- Value
- $200M
- Counterparty
- Bank of America, N.A.
- Term
- 5 years